TD Cowen reiterates Cigna stock Buy rating on strong quarter By Investing.com

Cigna reported Q1 2026 EPS of $7.79, beating the $7.61 consensus, on revenue of $68.52 billion versus $66.2 billion expected, and raised full-year guidance. TD Cowen reiterated a Buy rating and $338 price target, citing 20% adjusted pre-tax income growth in Specialty and Care Services and a 79.8% medical care ratio that beat the 81.0% consensus. Analyst sentiment is broadly positive, with multiple firms lifting targets to the $330-$340 range.

Analysis

CI is becoming a cleaner-quality compounder, but the market may still be underestimating how much of the quarter was mix-driven rather than purely cyclical. The key second-order read-through is that Specialty and Care Services outperformance can offset softness in legacy benefits economics, which should support a higher multiple if management can keep reinvesting into higher-margin adjacencies. That said, the stock is now vulnerable to “good quarter, lower surprise” risk over the next 1-2 reporting periods as expectations reset upward.

The biggest fundamental lever is not the near-term EPS beat; it is the duration of margin expansion in the specialty platform. If biosimilar contribution and care delivery cross-sell continue to scale, the company could sustain earnings growth even if utilization trends normalize, which would pressure bear cases that still model mean reversion too quickly. Conversely, any sign that pharmacy margin pressure is structurally worsening would matter more than headline revenue growth, because the market is implicitly paying for earnings durability, not top-line acceleration.

Consensus appears to be treating this as a straightforward valuation rerate, but the risk-reward is more nuanced. At this point, the cleaner trade may be relative value versus other managed-care names rather than an outright momentum chase, since upward estimate revisions have already started to compress the gap between reported performance and investor expectations. The contrarian miss is that if this is the first leg of a multi-quarter inflection in specialty economics, CI can keep outperforming even without multiple expansion; if not, the stock likely stalls once the next set of estimates fully incorporates the raised guide.

Key Decisions for Investors

• Maintain/establish a long CI position on any 2-3% post-rally pullback, targeting a 3-6 month horizon; favorable setup is continued estimate revision support with downside anchored by improving specialty mix.
• Pair trade: long CI / short a slower-growth managed-care peer over the next 1-2 quarters to isolate relative earnings momentum; this favors CI if specialty and care services keep compounding while the short leg faces more normalized utilization.
• Buy CI call spreads 3-6 months out instead of outright calls to capture potential rerating while limiting premium paid now that expectations have moved higher; best if implied volatility remains contained.
• Reduce or avoid chasing after a strong gap-up open; risk/reward is less attractive for the next 2-4 weeks unless there is a broader healthcare selloff that resets entry points.